CELSION CORPORATION (NASDAQ:CLSN) Files An 8-K Financial Statements and Exhibits

CELSION CORPORATION (NASDAQ:CLSN) Files An 8-K Financial Statements and Exhibits
Item 9.01Financial Statements and Exhibits.

Story continues below

(d)Exhibits.

Exhibit

No.

Description

16.1

Letter of Dixon Hughes Goodman LLP, dated September 21, 2017

16.2

Letter of Stegman and Company, dated September 21, 2017


Celsion CORP Exhibit
EX-16.1 2 ex_95789.htm EXHIBIT 16.1 ex_95789.htm Exhibit 16.1          September 21,…
To view the full exhibit click here

About CELSION CORPORATION (NASDAQ:CLSN)

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

An ad to help with our costs